Myasthenia gravis outcome measure: development and validation of a disease-specific self-administered questionnaire
- PMID: 12235493
- DOI: 10.1007/s100720200027
Myasthenia gravis outcome measure: development and validation of a disease-specific self-administered questionnaire
Abstract
We describe the development and validation of an outcome measure for patients with myasthenia gravis (MG) and show the correlation of the items with conventional MG measurements. In stage I, item generation, a group of methodologists, clinical experts generated a list of 56 items. The list was based on (1) a previous study on an MG sample, (2) clinical experience and (3) items proposed by MG patients. In stage 2, reduction of items, the list was reduced on the basis of results from field testing (41 patients completed the 56-item questionnaire). In stage 3, reliability and validity were assessed. A 25-item MG questionnaire (MGQ) was generated. Results were related to conventional measures of MG severity. Furthermore, the MGQ appeared reliable, sensitive and reproducible. The questionnaire was validated as an outcome measure.
Similar articles
-
Outcome Measures in Clinical Trials of Patients With Myasthenia Gravis.Front Neurol. 2020 Dec 23;11:596382. doi: 10.3389/fneur.2020.596382. eCollection 2020. Front Neurol. 2020. PMID: 33424747 Free PMC article. Review.
-
Validation of the Swedish version of the disease-specific Myasthenia Gravis Questionnaire.Neurol Sci. 2006 Jun;27(2):91-6. doi: 10.1007/s10072-006-0606-y. Neurol Sci. 2006. PMID: 16816904
-
Myasthenia gravis self-administered questionnaire: development of regional domains.Neurol Sci. 2005 Feb;25(6):331-6. doi: 10.1007/s10072-004-0366-5. Neurol Sci. 2005. PMID: 15729496
-
Correlation between a patient-derived functional questionnaire and abnormal neuromuscular transmission in Myasthenia Gravis patients.Clin Neurophysiol. 2005 Sep;116(9):2058-64. doi: 10.1016/j.clinph.2005.05.017. Clin Neurophysiol. 2005. PMID: 16043394 Clinical Trial.
-
[Caregiver burden in relatives of persons with schizophrenia: an overview of measure instruments].Encephale. 2003 Mar-Apr;29(2):137-47. Encephale. 2003. PMID: 14567165 Review. French.
Cited by
-
Clinical Outcome Assessments: Conceptual Foundation-Report of the ISPOR Clinical Outcomes Assessment - Emerging Good Practices for Outcomes Research Task Force.Value Health. 2015 Sep;18(6):741-52. doi: 10.1016/j.jval.2015.08.006. Epub 2015 Aug 24. Value Health. 2015. PMID: 26409600 Free PMC article.
-
Major motor-functional determinants associated with poor self-reported health-related quality of life in myasthenia gravis patients.Neurol Sci. 2016 May;37(5):717-23. doi: 10.1007/s10072-016-2556-3. Epub 2016 Apr 1. Neurol Sci. 2016. PMID: 27038315
-
Validation of the MG-DIS: a disability assessment for myasthenia gravis.J Neurol. 2016 May;263(5):871-882. doi: 10.1007/s00415-016-8072-9. Epub 2016 Mar 1. J Neurol. 2016. PMID: 26931109
-
Evaluation of a scale of patient-reported outcomes for the assessment of myasthenia gravis patients in China.Chin J Integr Med. 2012 Oct;18(10):737-45. doi: 10.1007/s11655-011-0944-3. Epub 2012 Feb 27. Chin J Integr Med. 2012. PMID: 22370869
-
Outcome Measures in Clinical Trials of Patients With Myasthenia Gravis.Front Neurol. 2020 Dec 23;11:596382. doi: 10.3389/fneur.2020.596382. eCollection 2020. Front Neurol. 2020. PMID: 33424747 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical